CTKB insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| MUIR GLENN P Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 47840 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter. | 2026-11-18 | 2026-11-20 | 4,629 shares/units | SEC 4 | Follow |
| MUIR GLENN P Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 7715 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 4,629 shares/units | SEC 4 | Follow |
| Holder Michael Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 5095 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2024; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter. | 2026-11-18 | 2026-11-20 | 2,181 shares/units | SEC 4 | Follow |
| Holder Michael Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 65056 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 2,181 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 189615 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 14,220 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 57526 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 6,162 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 29470 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 5,525 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 9826 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 7,363 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 4847037 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 3,463 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 4850500 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 14,220 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 4836280 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 1,501 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 4837781 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 6,162 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 4831619 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 1,346 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 4832965 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 5,525 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 4827440 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 1,793 shares/units | SEC 4 | Follow |
| Yan Ming CHIEF TECHNOLOGY OFFICER · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 4829233 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 7,363 shares/units | SEC 4 | Follow |
| Chin Richard Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 38683 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter. | 2026-11-18 | 2026-11-20 | 6,107 shares/units | SEC 4 | Follow |
| Chin Richard Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 34606 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 6,107 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 213993 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 16,049 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 121811 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 13,051 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 37929 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 12/48 of the total shares underlying the RSU Award vesting on May 18, 2025; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter. | 2026-11-18 | 2026-11-20 | 6,320 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 158193 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 5,401 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 163594 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 16,049 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 147545 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 4,392 shares/units | SEC 4 | Follow |
| McCombe William D. Chief Financial Officer · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 151937 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 13,051 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.